Debora Fumagalli

ORCID: 0000-0002-0649-1942

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)”.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

European Journal of Cancer(2021)10.1016/j.ejca.2021.01.053

N/A

0.685DataRank · unranked

28 citations

Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman +37 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607

N/A

0DataRank · unranked

1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more